Endothelin in neurohormonal activation in heart failure

被引：3
作者：
Boerrigter, G [1 ]
Burnett, JC [1 ]
机构：
[1] Mayo Clin & Mayo Fdn, Cardiorenal Res Lab, Rochester, MN 55905 USA
来源：
CORONARY ARTERY DISEASE | 2003年 / 14卷 / 07期
关键词：
endothelin; endothelin-A receptor; endothelin-B receptor; antagonist; neurohormonal activation; congestive heart failure; endothelin-converting enzyme; atherosclerosis;
D O I：
10.1097/00019501-200311000-00004
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：495 / 500
页数：6
相关论文
共 34 条
  • [1] Garlichs CD, 1999, EUR J CLIN INVEST, V29, P12
  • [2] Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure
    Givertz, MM
    Colucci, WS
    LeJemtel, TH
    Gottlieb, SS
    Hare, JM
    Slawsky, MT
    Leier, CV
    Loh, E
    Nicklas, JM
    Lewis, BE
    [J]. CIRCULATION, 2000, 101 (25) : 2922 - 2927
  • [3] Effects of aging and subsequent exercise training on gene expression of endothelin-1 in rat heart
    Iemitsu, M
    Miyauchi, T
    Maeda, S
    Tanabe, T
    Irukayama-Tomobe, Y
    Goto, K
    Matsuda, M
    Yamaguchi, I
    [J]. CLINICAL SCIENCE, 2002, 103 : 152S - 157S
  • [4] Physiological and pathological cardiac hypertrophy induce different molecular phenotypes in the rat
    Iemitsu, M
    Miyauchi, T
    Maeda, S
    Sakai, S
    Kobayashi, T
    Fujii, N
    Miyazaki, H
    Matsuda, M
    Yamaguchi, I
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2001, 281 (06) : R2029 - R2036
  • [5] Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?
    Kalra, PR
    Moon, JCC
    Coats, AJS
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2002, 85 (2-3) : 195 - 197
  • [6] Endothelin system: The double-edged sword in health and disease
    Kedzierski, RM
    Yanagisawa, M
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2001, 41 : 851 - 876
  • [7] EVIDENCE FOR ENDOTHELIN-1-MEDIATED VASOCONSTRICTION IN SEVERE CHRONIC HEART-FAILURE
    KIOWSKI, W
    SUTSCH, G
    HUNZIKER, P
    MULLER, P
    KIM, J
    OECHSLIN, E
    SCHMITT, R
    JONES, R
    BERTEL, O
    [J]. LANCET, 1995, 346 (8977): : 732 - 736
  • [8] Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure
    Krum, H
    Gu, AG
    WilshireClement, M
    SacknerBernstein, J
    Goldsmith, R
    Medina, N
    Yushak, M
    Miller, M
    Packer, M
    [J]. AMERICAN HEART JOURNAL, 1996, 131 (02) : 337 - 341
  • [9] CIRCULATING AND TISSUE ENDOTHELIN IMMUNOREACTIVITY IN ADVANCED ATHEROSCLEROSIS
    LERMAN, A
    EDWARDS, BS
    HALLETT, JW
    HEUBLEIN, DM
    SANDBERG, SM
    BURNETT, JC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (14) : 997 - 1001
  • [10] Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001
    Louis, A
    Cleland, JGF
    Crabbe, S
    Ford, S
    Thackray, S
    Houghton, T
    Clark, A
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2001, 3 (03) : 381 - 387
1234